Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

All News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
44.85 USD +0.34% Intraday chart for Bristol-Myers Squibb Company -8.34% -12.59%
Apr. 26 S&P 500 Q1 earnings estimated growth improves; stocks up for week RE
Apr. 26 Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
S&P 500 Q1 earnings estimated growth improves; stocks up for week
RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51
MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating
MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51
MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65
MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
MT
Bristol Myers: positive opinion from the CHMP for Opdivo
CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer
DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40
MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating
MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55
MT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BU
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
CI
Health Care Drops Amid Mixed Earnings -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Decline Late Afternoon
MT
Sector Update: Health Care Stocks Drop in Afternoon Trading
MT
Sector Update: Health Care
MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating
MT
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall
MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company